Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6

R P Hasserjian, J Howard, A Wood, K Henry, B Bain

Abstract

Aims—Classic erythroleukaemia (acute myeloid leukaemia M6, or M6 AML) is defined as an excess of myeloblasts in an erythroid predominant background. Leukaemia variants in which the primitive blast cells are demonstrably erythroid are extremely rare and poorly characterised. Variably referred to as “true erythroleukaemia” or “acute erythremic myelosis”, they are often included within the M6 AML category even though they do not meet strict criteria for this type of AML. Methods—Two cases of acute erythroid neoplasia are presented with clinical, morphological, immunophenotypic, and cytogenetic analysis. Results—Both patients presented with profound anaemia, one in a setting of long standing myelodysplasia. Bone marrow examination revealed a predominant population of highly dysplastic erythroid cells in both cases. In one case, the liver was infiltrated by neoplastic erythroid cells. Both patients died within four months of diagnosis. Conclusions—This report illustrates that cases of acute leukaemia occur in which the dominant neoplastic cell is a primitive erythroid cell without an accompanying increase in myeloblasts. This does not preclude the neoplastic clone originating in a multipotent haemopoietic stem cell, as suggested by cases arising in patients with myelodysplasia. Acute erythremic myelosis should be recognised as a distinct variant of M6 AML.

Keywords: erythroleukaemia; erythremic myelosis; Di Guglielmo’s syndrome; M6 AML

The French–American–British (FAB) classification of acute myeloid leukaemia (AML) includes a category, M6 AML, in which there is an excess of myeloblasts in an erythroid dominant marrow.1 The erythroblasts are often dysplastic and it is generally accepted that they are part of the neoplastic clone. The FAB classification does not include a category for cases where the neoplastic cells are immature erythroid cells without there being an excess of myeloblasts. However, such cases have been described by others and have been variously designated acute erythromyelosis, acute erythremia, acute erythremic myelosis, erythroblastic leukaemia, erythroblastic myelosis, Di Guglielmo’s syndrome, Di Guglielmo’s disease, M6 AML, or M6 AML “variant.”2–10 We report two additional cases of aggressive acute leukaemia in which the neoplastic cells were clearly erythroid, without an excess of myeloblasts. These two cases are true erythroid neoplasms that should be recognised as a subset of acute leukaemia, as has been proposed recently by the World Health Organisation’s preliminary classification of acute leukaemia.11

Case reports

CASE 1

This patient was noted at age 30 in 1977 to have asymptomatic macrocytic anaemia when he was rejected as a volunteer blood donor. At that time, the haemoglobin concentration (Hb) was 122 g/litre with a mean corpuscular volume (MCV) of 112 fl. White blood cell (WBC) and platelet counts were normal. He required no transfusion or other treatment for several years. Past medical history revealed bilateral undescended testicles and hypogonadism, for which he had been receiving testosterone supplements. In 1983, the patient also developed rheumatoid arthritis.

In 1988, dysplastic features (anisocytosis, poikilocytosis, tear drop poikilocytes, and occasional myelocytes and blasts) were noted in the peripheral blood. Bone marrow cytogenetic analysis was normal. In 1992, his anaemia became more severe and bone marrow examination showed trilineage dysplasia consistent with refractory anaemia. By February 1998, his Hb had fallen to 90 g/litre and a trial of erythropoietin treatment was begun. His Hb continued to fall and by August 1998 he had become transfusion dependent. Repeat bone marrow examination at that time showed refractory anaemia with no excess of blasts. However, two weeks later his platelet count, which had previously been normal, had dropped to 29 × 109/litre. Hepatosplenomegaly developed together with an acute deterioration in liver function. A bone marrow aspirate and trephine biopsy and a transjugular liver needle biopsy were performed.

CASE 2

This 52 year old Somalian man presented to casualty with fatigue and melaena. Over the previous six months he had developed progressive tiredness, bilateral leg swelling, weight loss, and night sweats and, more recently, had noted epistaxis, haemoptysis, and central chest tightness at rest. During the three weeks before presentation he had received weekly blood transfusions, which temporarily relieved the chest tightness. On examination he had widespread bruises and petechiae, mild ankle oedema, and massive splenomegaly. He was apyrexic, normotensive, and had no
superficial lymphadenopathy. Full blood count revealed: Hb, 80 g/litre; MCV, 87.3; WBC, 5.0 × 10^9/litre, with neutrophil count 2.0 × 10^9/litre and platelet count 3.0 × 10^9/litre. Lactate dehydrogenase was greatly raised at 1315 IU/litre and liver function tests were normal. A bone marrow trephine biopsy was performed, but no bone marrow could be aspirated. Peripheral blood was sent for cytogenetic analysis.

Figure 1 Case 1. (A) Bone marrow aspirate smear showing large primitive cells with vacuolated cytoplasm. (B) The primitive cells comprise about 80% of the cells of the bone marrow biopsy section, but interspersed maturing myeloid forms are also present (haematoxylin and eosin stained). (C) The primitive cells have basophilic, vacuolated cytoplasm on Giemsa stain; note the maturing myeloid forms in the upper right section. (D) The primitive forms cluster within bone marrow sinuses, as shown by the CD34 immunohistochemical stain highlighting endothelial cells. (E) The immature cells are immunoreactive for β-sialoglycoprotein; note one binucleate erythroblast. (F) A liver biopsy shows similar cells, immunoreactive for β-sialoglycoprotein, within hepatic sinusoids.
Methods
Bone marrow aspirate samples were stained with May-Grünwald-Giemsa. Bone marrow trephine biopsy specimens from the posterior iliac crest were fixed in aceto-zinc-formalin, decalcified in 10% formic acid, and embedded in paraffin wax. Sections (3 µm) were stained with haematoxylin and eosin (H&E) and Giemsa and silver stain (Gordon and Sweet’s method) for reticulin. The liver core biopsy was fixed in 10% neutral buffered formalin and embedded and stained as above. For immunohistochemistry, dewaxed sections were incubated with the following monoclonal antibodies: CD34 (Qbend; Bionostics, Wyboston, UK), CD61 (Clone Y2/51; Dako, Cambridgeshire, UK), CD79a (Dako), neutrophil elastase (Clone NP57; Dako), β-sialoglycoprotein (Ret40F; a kind gift of David Mason, Oxford, UK), cytokeratin (Cam 5.2; a kind gift of the Imperial Cancer Research Fund, UK), glycoporphin C (Dako), CD68 (Clones KP1 and PGM1; Dako), CD138 (BB4; Serotec, Kidlington, UK), CD43 (Serotec), and VS38c (a kind gift of David Mason), or the following polyclonal rabbit antibodies: terminal deoxytransferase (TdT; BioGenix, San Ramon, California, USA), myeloperoxidase (Dako), and CD3 (Dako). After primary antibody application, slides were developed using a modified streptavidin–biotin technique.

Results
CASE 1
The bone marrow aspirate was nearly dry, yielding only a few primitive erythroid appearing cells with cytoplasmic vacuolation (fig 1A). The trephine biopsy specimen showed a greatly hypercellular marrow containing sheets of primitive cells comprising over 80% of the total cells (fig 1B). These cells had round nuclei with finely dispersed chromatin and nucleoli varying from small and round to elongated and large. Cytoplasm was abundant and on Giemsa stain was intensely basophilic (fig 1C). Frequent binucleate and giant forms were seen. One striking feature was the tendency of these primitive cells to form clusters within the bone marrow sinusoids (fig 1D). The remaining cells were an admixture of cells of the granulocytic series, small lymphocytes, and occasional megakaryocytes with hypolobated nuclei. Myeloblasts were not increased in number, and the granulocytic elements showed maturation to neutrophils and only minimal dysplasia. Reticulin was moderately increased (grade 2 of 4).
Immunoperoxidase studies revealed that the primitive marrow cells were immunoreactive for β-sialoglycoprotein, a highly specific marker of erythroid differentiation (fig 1E). The cells were CD34, CD20, CD68 (KP1), CD68 (PGM1), myeloperoxidase, neutrophil elastase, and CD61 negative.

The karyotype of bone marrow aspirate on two occasions was 46, XY.

The liver core biopsy showed a patchy intrasinusoidal and focal portal infiltrate of large cells, resembling the primitive cells of the trephine biopsy. These cells were β-sialoglycoprotein positive (fig 1F).

Based on the diagnosis of an erythroleukaemia variant involving bone marrow and liver, the patient was treated with mitoxantrone and oral hydroxyurea, but his transfusion requirement and hepatosplenomegaly increased, and a repeat bone marrow trephine showed persistent erythroid blasts. In early December 1998, he underwent non-myeloablative conditioning (total body irradiation at 200 cGy and cyclosporin A) and received an infusion of granulocyte colony stimulating factor (G-CSF) mobilised peripheral blood stem cells from his composite karyotype of fourteen metaphases. The karyotype of peripheral blood was 43–44,XY,−5,−7,del(12)(q24),−13,−14, add(16)(p1), −17,−19,add(19)(p1),4±5mar (composite karyotype of fourteen metaphases).

The patient was initially managed with blood and platelet transfusions. Four days after admission he had an episode of supraventricular tachycardia which responded to adenosine. Over the next two days he suffered further episodes of chest pain and melaena. Despite continued transfusion support, he died six days after admission from a probable intracranial haemorrhage. A necropsy was not performed.

Discussion

These two cases represent true erythroid neoplasms in that the neoplastic cells morphologically and immunophenotypically resembled primitive erythroblasts, and myeloblasts were not increased even as a proportion of non-erythroid cells. In fact, although infrequent in both cases, identifiable granulocytic elements showed no or minimal dysplasia. In contrast, the erythroid elements occupied most of the bone marrow and consisted almost exclusively of early and highly dysplastic forms. Cytoplasmic vacuoles (prominent in one of our cases) and erythrophagocytosis by early erythroblasts have been observed in previously reported cases. In addition to morphological abnormalities, the early erythroblasts can contain large quantities of haemoglobin F.

Both of our cases had splenomegaly; in case 1, a liver biopsy showed hepatic infiltration by the neoplastic erythroid cells, thus demonstrating the capacity of these cells to behave in a malignant fashion. Di Guglielmo also noted hepatic and splenic infiltration in a patient with pronounced splenomegaly and moderate hepatomegaly. About one third of previously reported true erythroleukaemia patients (table 1) had clinically recognised hepatosplenomegaly. However, it is interesting to note that

Table 1 Presenting clinical features and survival of current and previously reported true erythroleukaemia cases

<table>
<thead>
<tr>
<th>No of cases</th>
<th>Splenomegaly</th>
<th>Hepatomegaly</th>
<th>Pancytopenia</th>
<th>Circulating proerythroblasts</th>
<th>Survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Di Guglielmo 1928**</td>
<td>1</td>
<td>1/1</td>
<td>1/1</td>
<td>1/1</td>
<td>1/1</td>
</tr>
<tr>
<td>Lazzaro 1933**</td>
<td>1</td>
<td>1/1</td>
<td>1/1</td>
<td>0/1</td>
<td>1/1</td>
</tr>
<tr>
<td>Stedmeister 1941**</td>
<td>1</td>
<td>1/1</td>
<td>1/0</td>
<td>0/1</td>
<td>1/0</td>
</tr>
<tr>
<td>Marchand et al 1983**</td>
<td>1</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
<td>0/1</td>
</tr>
<tr>
<td>Reiffers et al 1985**</td>
<td>2</td>
<td>1/2*</td>
<td>0/2*</td>
<td>2/2</td>
<td>2/2</td>
</tr>
<tr>
<td>Ruvicic et al 1986**</td>
<td>1</td>
<td>ND</td>
<td>ND</td>
<td>1/1</td>
<td>ND</td>
</tr>
<tr>
<td>Grieser and Horner 1987**</td>
<td>11</td>
<td>0/11</td>
<td>1/11</td>
<td>11/11</td>
<td>7/11</td>
</tr>
<tr>
<td>Kowal-Vern et al 1992**</td>
<td>13</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Tsuiji et al 1995**</td>
<td>1</td>
<td>1/1</td>
<td>1/1</td>
<td>1/1</td>
<td>0/1</td>
</tr>
<tr>
<td>Mazzella et al 1998**</td>
<td>15</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Hasserjian et al 2000</td>
<td>2</td>
<td>2/2</td>
<td>1/2</td>
<td>2/2</td>
<td>1/2</td>
</tr>
<tr>
<td>Total</td>
<td>49</td>
<td>7/20 (35%)</td>
<td>6/20 (30%)</td>
<td>19/21 (90%)</td>
<td>12/21 (57%)</td>
</tr>
</tbody>
</table>

*One case had no hepatosplenomegaly at presentation, but did have hepatic, splenic, and renal infiltration with pronormoblasts at necropsy.

**Median of all cases with survival data (40 in total).

ND, not determined or individually reported.
one case without apparent hepatosplenomegaly did show organ infiltration at necropsy, suggesting that the tendency of neoplastic erythroblasts to involve solid organs might be underestimated.

Cases of conventional erythroleukaemia often occur in the setting of a myelodysplastic syndrome. Among the reported true erythroleukaemia cases, nearly all patients had pancytopenia. Even in cases with circulating pronormoblasts, these were not usually frequent, the highest reported value being $7 \times 10^9$ litre$^{-1}$. In one of the current cases, the erythroleukaemia developed in the setting of a myelodysplastic syndrome. Past medical histories are not provided in most of the previously reported cases, but it is interesting to note that two of the cases in one of the series also had a past history of myelodysplasia. In addition, chromosome 5 and 7 losses or deletions, often associated with myelodysplastic syndromes, were present in one of our cases, paradoxically in the case without a history of myelodysplasia. Thirteen of 15 previously reported cases with cytogenetic data had losses and/or deletions in the long arms of chromosomes 5 and/or 7, and several cases had lost material from both of these chromosomes. Thus, many true erythroleukaemia cases may share a common pathogenetic mechanism with the more common myelodysplastic syndromes.

The erythroid cells in our cases had an intravascular growth pattern. This intravascular growth and propensity for solid organ infiltration is reminiscent of the rare entity of intravascular large B cell lymphoma, and implies the presence of a vascular adhesion molecule on the surface of these erythroid cells. Examination of more cases of this entity is needed, however, to determine if this is a consistent feature.

Acute leukaemia in which the dominant cell is a primitive erythroid cell, analogous to either a proerythroblast or an early (basophilic) erythroblast, should be recognised as a variant of acute leukaemia. The term “erythroleukaemia” is ambiguous, because it has also been used for M6 AML. Distinction from conventional M6 is important, because this true erythroleukaemia has a much poorer prognosis. The term “M6 variant AML” is suggested. Alternative designations would be acute erythremia or acute erythremic myelosis. In such M6 variant cases, the erythroid component is usually 80–100% of bone marrow nucleated cells. Although standardised criteria for true erythroleukaemia do not exist, Kowal-Vern et al proposed that cases in which erythroid cells comprise at least 50% of marrow cells and proerythroblasts comprise greater than 30% of all erythroid cells should be classified as such. Our two cases conform to this definition. In contrast to myelodysplastic syndromes with erythroid predominance, the neoplastic cells are primitive and sometimes barely recognisable as erythroid without the aid of immunophenotypic analysis or electron microscopy.

In summary, these cases indicate that true erythroleukaemia is a distinct form of acute leukaemia. Features of these and previously reported cases of this entity suggest an almost universal cytopenic presentation, with no or few circulating erythroblasts and hepatosplenic infiltration. Diagnosis of this unusual form of leukaemia can be difficult because of the lack of an excess of myeloblasts or circulating leukaemic cells. Because these neoplasms appear to behave very aggressively, with a median survival among current and previously reported cases of 1.5 months, prompt diagnosis is essential.

We thank S Parker for excellent technical assistance.

7 Bruning RD, McKenna RW. Tumors of the bone marrow. Washington, DC: Armed Forces Institute of Pathology, 1993:75.
Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6

R P Hasserjian, J Howard, A Wood, K Henry and B Bain

J Clin Pathol 2001 54: 205-209
doi: 10.1136/jcp.54.3.205

Updated information and services can be found at:
http://jcp.bmj.com/content/54/3/205

These include:

References
This article cites 18 articles, 1 of which you can access for free at:
http://jcp.bmj.com/content/54/3/205#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Immunology (including allergy) (1664)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/